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Abstract
In preeclampsia, maternal microvascular function is disrupted and angiogene-
sis is dysfunctional. Insulin resistance that occurs in some pregnancies also
pathologically affects microvascular function. We wished to examine the rela-
tionship of angiogenic mediators and insulin resistance on microvascular
health in pregnancy. We performed a nested, case–control study of 16 women
who developed preeclampsia with 17 normal pregnant controls. We hypothe-
sized that the impaired microvascular blood flow in preeclamptic women
associated with an increased ratio of the antiangiogenic factors; (s-endoglin
[sEng] and soluble fms-like tyrosine kinase-1 [sFlt-1]) and proangiogenic
molecule (placental growth factor [PlGF]) could be influenced by insulin
resistance. Serum samples taken after 28 weeks of gestation were measured for
the angiogenic factors, insulin, and glucose alongside the inflammatory mar-
ker; tumor necrosis factor-a and endothelial activation, namely; soluble vascu-
lar cell adhesion molecule 1, intercellular adhesion molecule-1, and e-selectin.
Maternal microvascular blood flow, measured by strain gauge plethysmogra-
phy, correlated with ratios of pro- and antiangiogenic mediators indepen-
dently of preeclampsia. Decreased microvascular function measured in
preeclampsia strongly correlated with both the antiangiogenic factor (sFlt-
1 + sEng): PlGF ratio and high levels of insulin resistance, and combining
insulin resistance with antiangiogenic factor ratios further strengthened this
relationship. In pregnancy, microvascular blood flow is strongly associated
with perturbations in pro- and antiangiogenic mediators. In preeclampsia, the
relationship of maternal microvascular dysfunction with antiangiogenic media-
tors is strengthened when combined with insulin resistance.
Introduction
In preeclampsia, generalized maternal endothelial dys-
function (Roberts et al. 1991) and inflammation is wide-
spread (Chambers et al. 2001) resulting in circulatory
changes (Roberts and Redman 1993; Levine et al. 2004)
influenced by factor(s) released by the ischemic placenta
(Anim-Nyame et al. 2015a, 2015b). The resulting multi-
system presentation of end organ damage, suggestive of
an underlying microvascular dysfunction, previously
demonstrated by our group (Anim-Nyame et al. 2003) is
preceded by reduced tissue perfusion (Anim-Nyame et al.
2001). Maternal endothelial dysfunction is considered to
be influenced either by the effects of mediators on a pre-
existing susceptible vasculature prior to the manifestation
of clinical preeclampsia (Savvidou et al. 2003) or by their
direct impact on the vasculature during pregnancy.
An elevation of circulating antiangiogenic factors con-
comitantly with a decrease in proangiogenic factors has
been found in preeclampsia and is associated with vascu-
lar endothelial dysfunction; however, how this affects the
microvasculature is unclear.
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In addition to the influence of circulating angiogenic
factors on microvascular function in preeclampsia, epi-
demiological studies have demonstrated an increased risk
of preeclampsia in pregnancies complicated by insulin
resistance (Caruso et al. 1999; Wolf et al. 2002; Seely and
Solomon 2003). Gestational insulin resistance associated
with preeclampsia has been associated with vascular dys-
function in large and small vessels (Anim-Nyame et al.
2015b). How insulin resistance may contribute to
preeclampsia is not well defined but there is a suggestion
that angiogenic and insulin-dependent pathways may
influence each other (Gerber et al. 1998; Kandel and Hay
1999; Autiero et al. 2003) with angiogenesis and insulin
resistance sharing molecular mechanisms of action (Chou
et al. 2002; Montagnani et al. 2002; Vicent et al. 2003).
Moreover, the proangiogenic effect of PlGF is strongly
influenced and modified by insulin resistance (Thadhani
et al. 2004).
In an effort to identify biomarkers that are pathologi-
cally linked to preeclampsia and associated vascular func-
tion, we tested the hypothesis that an interaction exists
between microvascular function, angiogenesis, and insulin
resistance in normal and preeclamptic pregnancies in a
nested case–control study.
Materials and Methods
In this prospective study of 33 pregnant women, 16
preeclamptic and 17 normotensive participants were
recruited after 28 weeks of gestation. The women were
similar in maternal age, gestational age, booking body
mass index (BMI), and ethnicity as previously described
(Anim-Nyame et al. 2015a).
Preeclampsia was defined as new onset hypertension
and proteinuria.
Participants
This prospective study enrolled women after 28 weeks of
gestation. Hypertension was defined as systolic blood
pressure ≥140 mmHg or diastolic blood pressure
≥90 mmHg, measured on at least two occasions, at least
4 h apart. Significant proteinuria was defined as urinary
protein excretion >300 mg/24 h (Chaiworapongsa et al.
2013).
Power calculations were based on a previous cross-
sectional study, with resting blood flow significantly
reduced in preeclampsia compared to normal pregnant
controls (1.95  0.9 mL/min/100 mL vs. 3.9  1.4 mL/
min/100 mL, P = 0.004, for preeclampsia and normal
pregnancy, respectively) (Anim-Nyame et al. 2000). Thus,
a sample size of 10 in each group was sufficient to achieve
statistical significance with a of 0.05 and b of 0.02. The
South London and Borders Local Ethics Committee
approved the study, and informed consent was obtained
from each participant. The study conformed to the Hel-
sinki Declaration.
Women with gestational diabetes or other metabolic,
cardiovascular, inflammatory, immune, infectious, or neo-
plastic conditions were excluded from the study, as were
smokers. The obstetric records of the women were
reviewed after delivery to confirm reversal of hypertension
and proteinuria in the preeclamptic group.
Blood sampling and assays
Blood samples were obtained from the antecubital vein
of each participant using aseptic techniques and col-
lected into EDTA tubes (4 mL) (Becton Dickenson,
Vacutainer System, UK). The serum was separated by
centrifugation at 1500 g for 10 min and stored at
80°C until assayed.
Human PlGF, sEng, sFlt-1, sICAM, sVCAM, e-selectin,
and TNF-a were measured by an enzyme linked
immunosorbent assay (ELISA) (R&D System Europe,
U.K.). These assays detect-free, but not bound growth
factors. All samples were collected, handled, and stored
under the same conditions and tested in duplicate. The
wells were read within 30 min using a plate reader at a
wavelength of 450 nm as per the manufacturer’s guideli-
nes (Labtech International, East Sussex, UK).
Microvascular blood flow was measured by strain gauge
plethysmography and determination of insulin resistance
was calculated from fasting maternal plasma glucose and
insulin concentrations. Insulin resistance was calculated
using the homeostasis model assessment (HOMA).
Measurement of blood flow
The study was performed in a quiet room with the tem-
perature kept constant between 24 and 25°C. Participants
were rested for at least 15 min before the study and blood
pressure was measured in triplicate with the mean reading
being used (Dinamap Vital Sign Monitor, Critikon, Fl).
Observations were made in the left lateral position to pre-
vent aortocaval compression, and with the right midcalf
supported at the level of the heart. Blood flow was mea-
sured using a Filtrass strain gauge plethysmograph (Fil-
trass; DOMED, Munich, Germany) (Anim-Nyame et al.
2001). The device is mercury-free, with an integrated
automatic calibration function that allows a touch-free
calibration, thus reducing artifacts due to investigator
manipulation. The sensor was calibrated automatically in
triplicate by a computer-driven program at the start of
each study. The Filtrass program is computer-assisted and
allows the selection of prerecorded protocols for
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measuring blood flow in the calf. The congestion pressure
cuff, which is attached to a built-in compressor pump,
was placed around the right thigh and enclosed in a rigid
corset to reduce filling volume and thus filling time.
Changes in calf circumference in response to a rapid
increase in thigh cuff pressure were measured using a pas-
sive inductive transducer with an accuracy of 5 lm.
The files were saved for subsequent off-line analysis.
Calf blood flow, measured in mLmin1100 mL1, was
measured using a protocol that has been described previ-
ously (Anim-Nyame et al. 2001). The venous congestion
pressure was raised rapidly to 40 mmHg and the pressure
held for 20 sec. Since this pressure occludes venous return
but not arterial blood inflow, the initial swelling rate
equals arterial blood flow. The change in circumference
of the calf was estimated from the slope of the first 3 sec
of the volume response to the pressure step. The flow was
measured at 3 sec -cuff inflation to remove variabilities in
the measurement of blood flow without the influence of
changes in capillary filtration and venous compliance
(Skoog et al. 2015).
This procedure was repeated three times with the con-
gestion pressure kept at zero for 5 min between each
measurement. The system’s analysis program calculates
the change in circumference and uses it to estimate vol-
ume change, assuming that the segment of calf being
studied is a cylinder of uniform diameter and constant
length. An ankle occlusion cuff was not used to exclude
contributions from non-nutritive flow through arteriove-
nous shunts of the feet. Maternal tissue blood flow was
measured in the calf, as it has a high muscle to skin ratio,
meaning blood flow through it relates to metabolic
requirements rather than thermoregulation. Moreover,
the skeletal muscle lacks arteriovenous channels and
therefore most of the measured arterial flow will traverse
the microvascular bed, thus representing the microvascu-
lar blood flow.
Statistical analysis
Normally distributed data were expressed as
mean  SEM and nonparametric data as median and
interquartile ranges. Univariate comparisons between
groups were analyzed using the Mann–Whitney test. For
univariate comparisons of blood flow analysis with
immunoassay data, the Kruskall–Wallis test was used.
Bivariate correlations were determined using Pearson
or Spearman correlation coefficients as appropriate. Mul-
tivariable logistic regression analyses explored relation-
ships between microvascular blood flow and circulating
mediators. Effect modification was examined using inter-
action terms in the logistic regression model. Values of
P < 0.05 were considered statistically significant. Statisti-
cal analysis was performed using SPSS version 22 (SPSS
Inc., Chicago, Ill).
Results
There was no significant difference in maternal age, book-
ing body mass index (BMI), or hematocrit between the
two groups (Table 1). As expected from the recruitment
criteria, women with preeclampsia had higher systolic
blood pressures (140.6  2.06 mmHg vs. 112.8 
2.87 mmHg, P < 0.0001; preeclamptic and normotensive
women, respectively) and diastolic blood pressures
(94.6  1.16 vs. 75.5  1.88 mmHg, P < 0.0001;
preeclamptic and normotensive women, respectively)
when compared with normotensive pregnant women.
Microvascular blood flow was reduced in the
preeclamptic group when compared with the normal
Table 1. Demographic and clinical data.
Variable
Normal pregnancy
(n = 17)
Preeclampsia
(n = 16) P value*
Age (years) 33.24  1.28 34.11  0.52 NS
BMI (kg/m2) 25.87  0.95 23.87  0.91 NS
Systolic BP (mmHg) 112.76  2.87 140.63  2.06 <0.0001*
Diastolic BP (mmHg) 75.47  1.88 94.56  1.16 <0.0001*
Mean arterial pressure (mmHg) 87.90  1.92 109.92  1.24 <0.0001*
Hematocrit 0.38  0.00719 0.326  0.01038 NS
Platelets (9106/mL) 275  12.00068 145  9.57 <0.0001*
Birth weight (g) 3365  165.39 2742  197.97 <0.05
Gestational age (weeks)
(at recruitment)
34.58  0.48 34.11  0.52 NS
Values represent mean  SEM. Values compared between preeclamptic patients and normotensive patients, unpaired t-test, *P < 0.05. SBP,
systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; BMI, body mass index; NS, not significant.
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pregnant controls (1.13 [0.94–1.54] vs. 4.06 [2.98–5.61]
mLmin1100 mL1, P < 0.0001, respectively) and corre-
lated inversely with systolic blood pressure, diastolic
blood pressure, and MAP (r = 0.659, P < 0.0001;
r = 0.586. P < 0.0001; r = 0.644, P < 0.0001) when
including all pregnancies.
Levels of inflammatory markers,
antiangiogenic factors, and insulin
resistance are elevated in preeclampsia
Serum PlGF was reduced in the preeclamptic group com-
pared with normal pregnant women (26.5 [15.72–43.07]
vs. 76.19 [62.95–182.56] pg/mL; P < 0.005, respectively.
Conversely, serum sFlt-1 was increased in the preeclamp-
tic group compared with the normotensive pregnancies
(1448.69 [1173.29–1584.52] vs. 758.31 [639.11–1087.29]
pg/mL, P < 0.005, respectively) as was sEng (9.68 [9.49–
10.02] vs. 4.44 [3.83–5.23] ng/mL; P < 0.0001, respec-
tively). All three biomarkers correlated with systolic blood
pressure (r = 0.58, P < 0.005; r = 0.583 P < 0.005;
r = 0.856 P < 0.0001, for PlGF, sFlt-1, and sEng, respec-
tively), diastolic blood pressure (r = 0.477, P < 0.01;
r = 0.589 P < 0.005; r = 0.869 P < 0.0001, for PlGF, sFlt-
1, and sEng, respectively) and MAP (r = 0.644,
P < 0.001; r = 0.591 P < 0.0001; r = 0.9 P < 0.0001, for
PlGF, sFlt-1, and sEng, respectively) when including all
pregnancies.
Circulating markers of endothelial activation and
inflammation (sICAM, sVCAM, e-selectin, and TNF-a)
were elevated in the preeclamptic group when compared
to normotensive controls (Table 2) as were circulating
free glucose and insulin levels. When calculated as a
homeostasis model of insulin resistance (HOMA-IR), this
was also significantly elevated in preeclamptic women
when compared to normotensive controls (Table 2).
PlGF influences vascular function following
multivariable adjustment
Analysis of both normotensive and preeclamptic subjects
together with microvascular function set as the outcome
measure demonstrated a significant relationship with
PlGF (r = 0.878, P < 0.0001), that following adjustment
for preeclampsia and circulating mediators that included:
sFlt-1, sEng, HOMA-IR, TNF-a, sICAM, sVCAM, and
Table 2. Microvascular blood flow and circulating mediators.
Variable
Normal pregnancy
(n = 17)
Preeclampsia
(n = 16) P Value
Tissue blood flow
(mL/100 mL/min)
4.06 (2.98–5.61) 1.13 (0.94–1.54) <0.0001*
sICAM (ng/mL) 58.99 (44.43–71.80) 195.18 (184.9–239.3) <0.0001*
sVCAM (ng/mL) 294.62 (239.48–331.26) 808.3 (703.37–866.11) <0.0001*
eSelectin (ng/mL) 12.42 (4.23–22.09)1 24.35 (14.60–49.25)2 <0.05*
TNF-a (pg/mL) 14.40 (12.92–15.57) 20.81 (19.23–22.71) <0.0001*
PlGF (pg/mL) 76.19 (62.95–182.58) 26.54 (15.72–43.07) <0.005*
sEng (ng/mL) 4.44 (3.83–5.23) 9.68 (9.49–10.02) <0.0001*
sFlt-1 (pg/mL) 758.31 (639.11–1087.29) 1448.69 (1173.29–1584.52) <0.005*
sFlt-1:PlGF (pg/mL) 9.14 (3.87–14.12) 45.16 (28.1–99.59) <0.0001*
(sFlt-1 + sEng):PlGF (pg/mL) 70.16 (27.19–111.22) 420.26 (250.21–728.67) <0.0001*
Data represent median  interquartile range. Unpaired t-test between preeclamptic patients and normotensive patients, *P < 0.05; 1(n = 16);
2(n = 15).
Table 3. Fasting glucose and insulin levels and insulin resistance (HOMA-IR) at recruitment.
Serum factor
Normal pregnancy
(n = 17)
Preeclampsia
(n = 16) P Value
Free insulin (lU/mL) 6.67 (5.42–10.21) 18.22 (16.98–21.56) <0.0001*
Free glucose (mg/dL) 91.30 (83.49–103.0010) 121.32 (111.56–128.53) <0.0001*
HOMA-IR 1.69 (1.17–2.52) 5.50 (5.02–5.91) <0.0001*
*P < 0.05.
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e-selectin, was maintained as having the strongest rela-
tionship with vascular function (b = 0.825, P < 0.0001).
The only other mediator to maintain a significant rela-
tionship with vascular function was sEng; however, the
variance inflation factor was high enough (VF = 13.46) to
suggest its behavior was nonspecific and influential in
other areas.
The correlation between (sFlt + sEng):PlGF
and microvascular function is maintained in
pregnancy independently of disease
Serum levels of PlGF, sEng, and sFlt-1 were then
expressed as a ratio of antiangiogenic:proangiogenic
mediators that were elevated in preeclampsia when com-
pared to normal pregnancy (420.26 [250.21–728.67] vs.
70.16 [27.19–111.22] pg/mL, P < 0.0001, respectively).
The ratio of (sFlt+sEng):PlGF correlated with microvas-
cular function when analyzed in all pregnancies
(R2 = 0.791, P < 0.001), Figure 1. This ratio of
(sFlt + sEng):PlGF also correlated with systolic blood pres-
sure (r = 0.736, P < 0.0001), diastolic blood pressure
(r = 0.614, P < 0.0001), and MAP (r = 0.695, P < 0.0001)
across all pregnancies.
Insulin resistance correlated with vascular function
upon analysis of the preeclamptic group but not in nor-
motensive pregnancies (r = 0.991 P < 0.0001 and
r = 0.047, P = NS, respectively), Figure 2.
The suggestion of an effect modification or interaction
of insulin resistance with the ratio of circulating angio-
genic factors was explored further. Creating a new uni-
variate model, the influence of the angiogenic factors
combined with insulin resistance on microvascular
function as an outcome measure was investigated using
the interaction term ((sFlt + sEng):PlGF) x Insulin Resis-
tance), and demonstrated statistical significance only in
the preeclamptic cohort (b = 0.001, P < 0.05). This rela-
tionship clearly differentiated preeclamptic from nor-
motensive pregnancies (Fig. 3).
Discussion
This study is the first to examine the relationship between
microvascular blood flow, circulating markers of
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Figure 1. Relationship between (sFlt-1 + sEng):PlGF (pg/mL) and
microvascular blood flow. Open circles normotensive pregnancies,
closed circles preeclamptic pregnancies. R2 = 0.791.
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Figure 2. Relationship between insulin resistance (HOMA-IR) and
microvascular blood flow. Insulin resistance correlated with vascular
function only upon analysis of the preeclamptic group and not in
normotensive pregnancies (r = 0.991 P < 0.0001; r = 0.047,
P = NS, respectively). Open circles normotensive pregnancies, closed
circles preeclamptic pregnancies.
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Figure 3. Relationship between insulin resistance (HOMA-IR) and
(sFlt-1 + sEng):PlGF (pg/mL). Open circles normotensive
pregnancies, closed circles preeclamptic pregnancies.
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angiogenesis, insulin resistance, and endothelial activation
together in preeclampsia.
Decreases in microvascular blood flow were associated
with elevations in antiangiogenic mediators in both
healthy pregnancy and preeclampsia. The observed
decrease in blood flow in preeclampsia was also associated
with elevations in insulin resistance and circulating mark-
ers of endothelial activation and inflammation.
In pregnancy, transient increases in insulin resistance
and inflammatory responses are considered normal along-
side increased angiogenesis. Maternal venous capacitance
increases, arterial resistance decreases, and vasodilatation
increases are accompanied by an increase in blood vol-
ume (Carpenter 2007); however, in preeclampsia, these
mechanisms become dysfunctional, manifested by mater-
nal hypertension and end organ damage.
In the current study, we have found that the levels of
circulating angiogenic biomarkers are strongly associated
with vascular function independent of disease. The influ-
ence of angiogenesis on the progression of preeclampsia
has been well established with the balance between pro-
and antiangiogenic factors identifying women who will
develop preeclampsia (Levine et al. 2004; Verlohren et al.
2012a; Chaiworapongsa et al. 2013). Whether these alter-
ations are a primary event in the development of the dis-
ease or secondary to placental perfusion remains unclear.
It is known that the preeclamptic maternal vasculature is
dysfunctional, with recent evidence demonstrating a dys-
function in the production of mRNA and protein of
antiangiogenic factors and proangiogenic factors in
microvascular endothelial cells (Lee and Nevo 2016).
When the association of microvascular function and
(sFlt + sEng):PlGF in preeclamptic women was coupled
with insulin resistance, this relationship was amplified. It
is known that the risk of preeclampsia associated with
decreased PlGF levels are increased with hyperinsulinemia
(Thadhani et al. 2004), suggesting that pathological alter-
ations in either or both of these pathways may provide
additive insults that create widespread injury.
This study, that includes the influence of sFlt, sEng,
and PlGF with insulin resistance and microvascular dys-
function, highlights the importance of signaling pathways
consequent to VEGF and insulin binding, suggest com-
mon pathways downstream of the receptors. Thus, alter-
ations in signaling involving SFlt-1, PlGF, and insulin
may provide summative insults that lead to widespread
endothelial activation and injury culminating in vascular
dysfunction. Insulin itself has been considered a primary
pathophysiological effector in hypertension (Wu et al.
1994), associated with elevated circulating noradrenaline
(Anderson et al. 1991) and renal sodium retention
(DeFronzo et al. 1976). Studies of the vasodilatory actions
of insulin have revealed that insulin can act in a nitric
oxide-dependent fashion (Clark et al. 2003) that precedes
the induction of glucose uptake (Vincent et al. 2004),
suggestive of a primary effect of insulin on the vascula-
ture and not secondary to changes in cellular metabolism.
In preeclampsia, the antiangiogenic imbalance of
mediators that is associated with a decreased microvas-
cular blood flow and exacerbated by high levels of insu-
lin resistance are not observed in healthy pregnancy.
These measurements could become a useful tool to
assess the severity of multisystem dysfunction in
preeclampsia as reduced tissue perfusion precedes end
organ dysfunction.
Following pregnancy, it has been suggested that the
persistence of subclinical inflammation, antiangiogenic
proteins (Kvehaugen et al. 2011) and insulin resistance in
women with preeclampsia results in an increased cardio-
vascular risk (Wolf et al. 2004) that potentially could be
manifested as cardiovascular disease following exposure to
other risk factors (Sattar and Greer 2002). Defining the
risk associated with the ratio of antiangiogenic factors to
proangiogenic factors, insulin resistance, and microvascu-
lar function justifies investigating this relationship earlier
in pregnancy with an aim to promoting early interven-
tion. Another strategy would be to investigate this disease
after pregnancy to follow up any resolution of vascular
damage, to promote early intervention and prevent future
cardiovascular disease. Currently, no validated test exists
that reliably predicts progression of preeclamptic pathol-
ogy and therefore preeclamptic women who do not
require immediate delivery are monitored as inpatients
until timely delivery (Visintin et al. 2010). As the serum
sFlt-1:PIGF ratio correlates with the severity of
preeclampsia (Verlohren et al. 2012b) and our data
demonstrates that the microvascular blood flow (which
precedes end organ dysfunction (Powe et al. 2011)) inver-
sely correlates with both sFlt-1:PIGF and sFlt-1 + sEng:
PlGF, our data supports the clinical use of an antiangio-
genic:proangiogenic ratio to identify preeclamptic women
who may be at risk of underlying organ dysfunction and
be more likely to deteriorate, requiring urgent interven-
tion (Verlohren et al. 2012a) and early delivery.
Limitations
A limitation of this study is the small sample size. Identi-
fying interactions between variables is often difficult
because of the requirement for large sample sizes for for-
mal statistical testing; as a consequence these tests should
only be used as a guide (Rothman and Greenland 1998).
Although women in this study had mild preeclampsia,
there was a significant relationship between microvascular
blood flow, antiangiogenic factor ratio and insulin
resistance.
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We acknowledge that a subsequent study with a larger
sample size including women with early onset and severe
preeclampsia, and other conditions associated with insulin
resistance would improve the accuracy of our findings in
relation to the pro- and antiangiogenic balance.
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